The global brain tumor treatment market is expected to garner a market value of USD 3,114.2 million in 2023 and is expected to accumulate a market value of USD 6,228.2 million by 2033, registering a CAGR of 7.2% in the forecast period. The rising prevalence of such cancer and the growing geriatric population are key drivers expected to nurture the growth of the brain tumor diagnosis market worldwide. The market for brain tumor treatment registered a CAGR of 4.7% in the historical period.
| Data Points | Key Statistics |
|---|---|
| Brain Tumor Treatment Market Value 2023 | USD 3,114.2 million |
| Brain Tumor Treatment Market Projected Value (2033) | USD 6,228.2 million |
| Brain Tumor Treatment Market CAGR (2023 to 2033) | 7.2% |
A brain tumor is an abnormal and uncontrolled proliferation of cells in the brain. It can be benign or malignant. Brain tumor arises from brain tissue and rarely spreads. The tumor eventually compresses and damages other structures in the brain. According to American Brain Tumor Association (ABTA), there are two types of brain tumors - primary and secondary. Primary tumors arise from brain tissue and secondary tumors arise from other parts of the body and spread to the brain.
Gliomas are the most common type of primary tumor which arises from the brain’s glial tissue. Glioblastoma multiform is fast-growing and of a higher grade when compared to other tumors. Advanced medications are available to treat brain tumors. Increasing pharmaceutical Research and Development spending is expected to provide lucrative growth for the global brain tumor treatment industry over the forecasted period.
Based on region, North America is estimated to capture the highest share owing to the advanced healthcare facilities and hefty investment in the research program to find an effective treatment for brain tumors.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The global demand for brain tumor treatment is projected to increase at a CAGR of 7.2% during the forecast period, reaching a total of USD 6,228.2 million in 2033, according to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 4.7%.
Over the years, accelerating research activities in the oncology sector and increasing adoption of advanced technologies for cancer treatment have augmented the demand for brain tumor therapeutics across the globe.
According to the Central Brain Tumor Registry of the USA (CBTRUS) statistical report of 2016, an estimated 79,270 new cases of primary malignant, non-malignant, and other CNS cancers were diagnosed in the United States in 2020 (26,070 primary malignant and 53,200 non-malignant). Thereby, the increasing prevalence of brain cancer cases across the globe is expected to propel the demand for brain tumor diagnosis/treatment throughout the forecast period.
Growing on Chemotherapies and Increasing Awareness to Act as Principal Growth Drivers
An increase in the prevalence rate of brain tumors has fueled the demand for effective treatment. For instance, as per the American Society of Clinical Oncology (ASCO), the brain tumor incidence rate growing by 2.6% compared to the last year. An estimated 22,850 cases are diagnosed with primary cancerous tumors of the brain in the United States. Furthermore, the increasing geriatric population is also driving the brain tumor market.
As such, global companies are spending a significant portion of their revenue on Research and Development to develop novel medications. Numerous products related to novel drug delivery technologies are lined up for FDA approval. Increasing demand for advanced medication to treat brain tumors is expected to fuel the overall growth of the market. Increasing consumer awareness regarding the latest technological advancements in therapies, and medications are responsible for the growth of the global brain tumor treatment market.
Principal Consultant
High Cost of Treatment May Hamper the Market Expansion of the Brain Tumor Treatment Market
Successfully treating brain tumors can be challenging. The body’s blood-brain barrier normally protects the brain and spinal cord from harmful chemicals. However, this barrier also keeps out many types of chemotherapy. Surgery can be difficult if the tumor is near a delicate part of the brain or spinal cord. Even when the surgeon can completely remove the original tumor, parts of the tumor may remain that are too small to be seen or removed during surgery. Radiation therapy can also damage healthy tissue.
However, research in the past 20 years has helped to significantly lengthen lives and improved the quality of life for many people with brain tumors. These advancements include more refined surgeries, a better understanding of which types of tumors respond to chemotherapy and other drugs, and more targeted delivery of radiation therapy. Besides, the higher initial cost of treatment and clinical trials may act as major roadblocks over the coming years.
Advanced Healthcare Infrastructure & Presence of Innovative Research Centers Nurture the Demand for Brain Tumor Treatment
| Region | North America |
|---|---|
| Market Share % (2022) | 34.2% |
North America region is expected to dominate the global brain tumor treatment market throughout the forecast period, owing to increasing incidences of glioblastoma coupled with technological advancements. North America is expected to account for more than 34.2% share of the global brain tumor treatment market in 2023. Advanced healthcare infrastructure, greater per capita healthcare spending, and comparatively higher awareness regarding advanced technologies are certain to impact rendering factors.
Besides, the presence of advanced healthcare facilities and innovative research centers is another reason for fueling the demand for brain tumor treatment & therapeutics. For instance, the UCSF Brain Tumor Center is one of the largest and most comprehensive programs in the region for the treatment of brain and spinal tumors. This center includes advanced intra-operative imaging and brain mapping techniques to protect areas of the brain used for language, motor skills, and sensory function during surgery, as well as radiosurgery with Gamma Knife and CyberKnife and access to clinical trials of promising new therapies.
Encouraging Healthcare Programs & Increasing Clinical Trials for Novel Drug Development to Spur Demand for Brain Tumor Treatment
| Region | Europe |
|---|---|
| Market Share % (2022) | 24.2% |
Europe is expected to contribute significantly to this space over the forecast period, which can be attributed to the increasing prevalence of malignant cancers in countries like the United Kingdom For instance, as per statistics provided by the Office for National Statistics, United Kingdom, in 2021, around 11,000 new cases were registered in the region.
Europe is the second largest in terms of market revenue and is estimated to witness significant gains throughout the forecast period. As per Future Market Insights, Europe is slated to account for a 21% share of the global brain tumor treatment market. This market growth is attributed to the increasing emphasis on cancer research and the rising prevalence of cancer cases in the region.
EANO is Europe’s multidisciplinary Neuro-Oncology organization representing all medical and scientific disciplines involved in the prevention, diagnosis, and treatment of tumors of the central nervous system (CNS). EANO is dedicated to promoting advances in Neuro-Oncology through innovative research and concerted education and training. Moreover, encouraging healthcare programs and the adoption of state-of-the-art technologies for the identification and treatment of malignant cancers in hospitals and healthcare facilities is likely to propel the brain tumor treatment market in the region.
Increasing Adoption of Cutting-edge Technology in Several Countries to Escalate the Market Growth of Brain Tumor Treatment
| Country | Market CAGR % (2023 to 2033) |
|---|---|
| China | 8.8% |
| India | 7.2% |
The Asia Pacific represents a significant share of the brain tumor treatment market and is projected to experience robust growth throughout the forecast period, states Future Market Insights report. A significant increase in the incidence rate of brain tumors along with the shifting of locus of economic activity and dynamism to this region is expected to boost the demand for drugs responsible for brain tumor treatment.
The development of novel drugs and increasing clinical trials have boosted the market growth of the brain tumor treatment market in the Asia Pacific region. Encouraging healthcare policies and smooth drug approval programs by FDA are other aspects driving the market for brain tumor treatment.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
| Report Attribute | Details |
|---|---|
| Growth Rate | CAGR of 7.2% from 2023 to 2033 |
| Market Value in 2023 | USD 3,114.2 million |
| Market Value in 2033 | USD 6,228.2 million |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Product, End User, Region |
| Regions Covered | North America; Latin America; Europe; Asia Pacific; Middle East and Africa |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, China, Japan, South Korea, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Genentech USA; Bristol Myers Squibb; Hoffmann- La Roche; AstraZeneca Plc.; Pfizer Inc.; Novartis AG; Antisense Pharma; Merck & Co; MacLeod’s Pharmaceutical Limited; Mankind Pharma; Siemens Healthineers AG; Dr. Reddy’s Laboratories Ltd. |
The market is forecast to register a CAGR of 7.2% through 2033.
The market is valued to hit USD 6,228.2 million by 2033.
The global market advanced at a 4.7% CAGR from 2018 to 2022.
The market is estimated to secure a valuation USD 3,114.2 million in 2023.
In 2023, North America may command a 34.2% market share.
The projected global market share for Europe is 24.2%.
The China market to record a market CAGR of 8.8% through 2033.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Product 5.1. Temozolomide 5.2. Carmustine 5.3. Cisplatin 5.4. Bevacizumab 5.5. Geftinib 5.6. Erlotinib 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User 6.1. Hospital Pharmacies 6.2. Ambulatory Surgical Centers 6.3. Individual Pharmacies 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. North America 7.2. Latin America 7.3. Western Europe 7.4. Eastern Europe 7.5. South Asia and Pacific 7.6. East Asia 7.7. Middle East and Africa 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. Key Countries Market Analysis 16. Market Structure Analysis 17. Competition Analysis 17.1. Genentech USA 17.2. Bristol Myers Squibb 17.3. Hoffmann-La Roche 17.4. AstraZeneca Plc. 17.5. Pfizer Inc. 17.6. Novartis AG 17.7. Antisense Pharma 17.8. Merck & Co 17.9. MacLeod’s Pharmaceutical Limited 17.10. Mankind Pharma 17.11. Siemens Healthineers AG 17.12. Dr. Reddy’s Laboratories Ltd. 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Brain Tumor Treatment Market
